Navigating the Side Effects: Our Insights on IV Ferric Carboxymaltose Study

Abstract

Background:Intravenous ferric carboxymaltose (brand name Ferinject) is commonly used to treat iron deficiency anemia. For many clinicians, it is the treatment of choice for severe iron deficiency requiring rapid correction. Intravenous ferric carboxymaltose (FCM) can be the treatment of choice in various medical conditions. It is also given when oral iron supplements are proven to be ineffective. Ferric carboxymaltose delivers iron directly into the bloodstream. This study aims to identify the incidence of adverse reactions in individuals who experienced side effects following ferric carboxymaltose (FCM) administration. We analysed patient demographics, types of reactions, and treatments administered.The study was conducted over a one-year period at the Abu Dhabi Stem Cells Centre (ADSCC) and Yas Clinic Hospital in Khalifa City (YCKC), the only licensed stem cell facility in the region. To the best of our knowledge, no published data on this topic exists for the Gulf region.Objective:

The primary objective of our study is to determine the incidence, type of reactions, and confounding factors that influence adverse reactions to the use of Ferric carboxymaltose.

Methods:

A retrospective observational study was conducted over a one-year period at YCKC (managed by ADSCC), UAE  from January 17 until December 28, 2023. 136 patients were included in this observational study who underwent ferric carboxymaltose infusion. All individuals included in this study had valid indications for infusion, as determined by the treating clinician. The data collected comprised patient demographics, severity of post-infusion reactions, and administered treatments. This information was analysed using the TRAKCARE medical records system of the hospital.

Results:136 patients were enlisted in the study, of whom 5 had sudden allergic reactions after the infusion. Based on the standard guidelines, the infusion rate depends on the weight of the patient and the target hemoglobin. As per the standard guidelines, the ferric carboxymaltose infusion duration is usually 10-15 minutes. In our study, the infusion was given in various doses and varying durations. All of the infusions given totalled 16.1-30.3 mg/min. All five patients in the study exhibited mild to moderate reactions, characterised by redness and itchiness on their bodies. Appropriate treatment was given to all patients.Conclusion:

The primary objective of this study was to assess the occurrence of adverse reactions to FCM and analyse any correlating factors. By analysing the incidence and nature of these adverse reactions, we aim to gain a deeper insight into the safety profile of Ferinject carboxymaltose and to identify any potential risk factors associated with its administration. This information is crucial for enhancing patient management and ensuring the safe and effective use of this treatment in clinical practice.